---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-039140"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2026-08-19T12:50:32+00:00"
generated_at: "2026-08-19T12:55:10.334078+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# INBS reports FY2026 revenue up 38% to $4.2M; gross margin expands to 48.63%

## Summary
- FY2026 revenue $4.2M, up 38% YoY from $3.05M; gross profit $2.05M, up 64% YoY.
- Gross margin 48.63%, up 778 bps from 40.85%; driven by Syrma Johari manufacturing transition.
- Reader installed base 1,886 units (+22% YoY); consumable cartridges 106,500 (+35%); 502 active customers.
- FDA 510(k) submission on track for H2 calendar 2026; all clinical data collection completed.
- New strategic partnership with Bouygues UK for drug-testing rollout; eighth European patent granted.

## SEC filing metadata
- accession: 0001493152-26-039140
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2026-08-19T12:50:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315226039140/0001493152-26-039140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315226039140/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-039140
- JSON: https://secwatch.observer/filing/0001493152-26-039140.json
- Plain text: https://secwatch.observer/filing/0001493152-26-039140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.